Strona główna・Stock List・OPKO Health Inc

OPKO Health Inc

Closed

SectorHealthcare

1.38 0.73

Buy Sell

Overview

Share price change

24h

Current

Min

1.3599999999999999

Max

1.4

Key metrics
By Trading Economics
Income	46M -8.4M
Sales	39M 164M
EPS	-0.01
Profit margin	-5.145
Employees	2,275
EBITDA	40M 12M

Recommendations
By TipRanks
Recommendations	Buy
12 Months Forecast	+118.98% upside

Dividends
By Acuity
Next Earnings	28 paź 2026

Market Stats
By TradingEconomics
Market Cap	72M 978M
Previous open	0.65
Previous close	1.38

News Sentiment

By Acuity

67%

33%

277 / 340 Ranking in Healthcare

OPKO Health Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

7 sie 2026, 23:01 UTC

OPKO Health shares advanced in after-market trading, recovering from earlier losses amid broader market dynamics and a slight decline in the unemployment rate.

6 sie 2026, 19:16 UTC

OPKO Health Inc. shares are lower today amid notable volatility, with economic data showing initial jobless claims rose slightly ahead of tomorrow's non-farm payrolls report.

5 sie 2026, 23:01 UTC

OPKO Health shares are lower in after-market hours, reflecting broader market weakness amid recent economic data showing weaker-than-expected U.S. job growth.

4 sie 2026, 23:06 UTC

OPKO Health Inc. shares are higher in after-market trading, settling with a cumulative gain following a brief dip at the session's start.

3 sie 2026, 23:01 UTC

OPKO Health Inc shares increased in after-market trading, maintaining a steady rise since Monday's close amid a generally positive market backdrop.

31 lip 2026, 19:45 UTC

OPKO Health Inc. shares are trading roughly flat today, hovering around the middle of their one-month range and above the 20-day moving average.

30 lip 2026, 23:11 UTC

OPKO Health Inc. shares are lower in after-market hours, continuing a recent trend amid broader market uncertainty following the Federal Reserve's interest rate decision.

29 lip 2026, 23:46 UTC

No specific news was identified for OPKO Health Inc. Shares remained roughly flat during after-market hours, trading near unchanged since Wednesday's close.

28 lip 2026, 23:41 UTC

News

OPKO Health reported a narrowed net loss of $8.4 million and raised revenue guidance, but shares are lower in after-market hours following recent gains.

27 lip 2026, 23:41 UTC

News

OPKO Health reported second-quarter revenues of $163.5 million, surpassing expectations. The company also raised its full-year sales guidance, boosting shares in after-market trading.

24 lip 2026, 22:06 UTC

OPKO Health Inc shares are higher in after-market trading, reaching a peak shortly after the market closed. No specific news was identified for this movement.

22 lip 2026, 18:31 UTC

OPKO Health is declining today, having pulled back from earlier gains amid broader market volatility and rising geopolitical tensions.

21 lip 2026, 22:56 UTC

No specific news was identified for OPKO Health during after-market hours. The stock remains roughly flat, positioned 12.60% below its 20-day moving average.

20 lip 2026, 19:51 UTC

OPKO Health Inc shares are higher in Monday's session, reflecting positive trading conditions. Broader market dynamics are supported by strength in Asian markets.

Peer Comparison

Price change

OPKO Health Inc Forecast

Price Target

By TipRanks

118.98% upside

12 Months Forecast

Average 3 USD 118.98%

High 3 USD

Low 3 USD

Based on 3 Wall Street analysts offering 12 month price targets forOPKO Health Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

3 ratings

Buy

Hold

Sell

Based on 3 analysts giving stock ratings to OPKO Health Inc - Dist in the past 3 months.

Sentiment

By Acuity

277 / 340 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About OPKO Health Inc

OPKO Health, Inc., a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Spain, Chile, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test. Its Pharmaceutical segment offers Rayaldee to treat secondary hyperparathyroidism in adults with stage 3 or 4 chronic kidney disease, and vitamin D insufficiency. This segment also develops multi-specific immune therapies focused on oncology, infectious diseases, vaccines, and immunology; OPK88004, an orally administered selective androgen receptor modulator; OPK88003, a once-weekly administered peptide for the treatment of type 2 diabetes and related obesity; Somatrogon (hGH-CTP), a once-weekly human growth hormone injection; and Factor VIIa-CTP, a novel long-acting coagulation factor being developed to treat hemophilia. In addition, it develops and commercializes longer-acting proprietary versions of already approved therapeutic proteins; develops and produces specialty APIs; develops, manufactures, markets, and sells pharmaceutical, nutraceutical, veterinary, and ophthalmic products; commercializes food supplements and over the counter products; manufactures and sells products primarily in the generics market; and markets, distributes, and sells pharmaceutical products in a range of indications, including cardiovascular products, vaccines, antibiotics, gastro-intestinal products, hormones, and others. The company also operates pharmaceutical platforms in Ireland, Chile, Spain, and Mexico. The company was founded in 2007 and is headquartered in Miami, Florida.